2021-04-07

School of Economics and Resource Management, Beijing Normal University, Beijing 100875, China.; Beijing Key Lab of Study on SCI-TECH Strategy for Urban Green Development, Beijing 100875, China.; School of Economics and Resource Management, Beijing Normal University, Beijing 100875, China.; School of Economics and Resource Management, Beijing Normal University, Beijing 100875, China.

Understanding the reasons for the differences in the spread of COVID-19 in different cities of China is important for future epidemic prevention and control. This study analyzed this issue from the perspective of population migration from Wuhan (the epicenter of the COVID-19 outbreak in China). It reveals that population outflow from Wuhan to other cities in Hubei Province (the province where Wuhan is located) and metropolises and provincial capitals outside of Hubei province exceeded those to other cities. This is broadly consistent with the distribution of confirmed COVID-19 cases. Additionally, model analysis revealed that population outflow from Wuhan was the key factor that determined the COVID-19 situations. The spread of COVID-19 was positively correlated with GDP per capita and resident population and negatively correlated with the distance from Wuhan and the number of hospital beds, while population density was not a strong influential factor. Additionally, the demographic

2021-03-14

The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.; Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.; Office of Global Engagement Chinese University of Hong Kong, Hong Kong SAR 999077, China.; Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.

OBJECTIVES: We examined if the WHO International Health Regulations (IHR) capacities were associated with better COVID-19 pandemic control. DESIGN: Observational study. SETTING: Population-based study of 114 countries. PARTICIPANTS: General population. MAIN OUTCOME MEASURES: For each country, we extracted: (1) the maximum rate of COVID-19 incidence increase per 100,000 population over any 5-day moving average period since the first 100 confirmed cases; (2) the maximum 14-day cumulative incidence rate since the first case; (3) the incidence and mortality within 30 days since the first case and first COVID-19-related death, respectively. We retrieved the 13 country-specific International Health Regulations capacities and constructed linear regression models to examine whether these capacities were associated with COVID-19 incidence and mortality, controlling for the Human Development Index, Gross Domestic Product, the population density, the Global Health Security index, prior exposure

2020-03-10

grid.54549.390000 0004 0369 4060Department of Cardiology, Sichuan Academy of; Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China grid.54549.390000 0004 0369 4060Department of Anesthesiology, Sichuan Academy of ; Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China grid.54549.390000 0004 0369 4060Department of Critical Care Medicine, Sichuan; Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China

2020-03-10

grid.54549.390000 0004 0369 4060Department of Cardiology, Sichuan Academy of; Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China grid.54549.390000 0004 0369 4060Department of Anesthesiology, Sichuan Academy of ; Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China grid.54549.390000 0004 0369 4060Department of Critical Care Medicine, Sichuan; Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 Sichuan Province China

2021-11-16

Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.; Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.; Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China.; Wuxi Lung Transplant Center, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, China.; Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.

INTRODUCTION: We report the case of a 65-year-old Coronavirus disease 2019 (COVID-19) patient with pneumonia and subsequent end-stage pulmonary failure who required 63 days of mechanical ventilation (MV) and 62 days of extracorporeal membrane oxygenation (ECMO). METHODS: On Day 45, a comprehensive interdisciplinary discussion on the best course of treatment resulted in the general consensus that his lungs would not recover. As such, he was evaluated and listed for a lung transplant. RESULTS: We performed a bilateral lung transplant, and the patient was weaned off ECMO and MV postoperatively. This is the first report of lung transplants in patients with COVID-19 in Wuhan. CONCLUSIONS: We suggest that a lung transplantation may be a viable treatment for patients with end-stage pulmonary failure secondary to COVID-19 in selected situations.CI - © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

2021-08-26

Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, 218 jixi road, shushan district, Hefei, Anhui, China.; Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, 218 jixi road, shushan district, Hefei, Anhui, China.; Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, 218 jixi road, shushan district, Hefei, Anhui, China.; Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, 218 jixi road, shushan district, Hefei, Anhui, China.; Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, 218 jixi road, shushan district, Hefei, Anhui, China. zhanghong20070703@163.com.

BACKGROUND: Covid-19 became a global pandemic in 2019. Studies have shown that coronavirus can cause neurological symptoms, but clinical studies on its neurological symptoms are limited. In this meta-analysis, we aimed to summarize the various neurological manifestations that occurred in COVID-19 patients and calculate the incidence of various neurological manifestations. At the same time, we further explored the mechanism of nervous system injury and prognosis in COVID-19 patients in combination with their nervous system manifestations. This study provides a reference for early clinical identification of COVID-19 nervous system injury in the future, so as to achieve early treatment and reduce neurological sequelae. METHODS: We systematically searched all published English literature related to the neurological manifestations of COVID-19 from January 1, 2020, to April 30, 2021, in Pubmed, Embase, and Cochrane Library. The keywords used were COVID-19 and terminology related to the

2021-07-28

School of Urban Design, Wuhan University, Wuhan 430072, China.; School of Urban Design, Wuhan University, Wuhan 430072, China.; School of Urban Construction, Wuhan University of Science and Technology, Wuhan 430072, China.; School of Urban Construction, Wuhan University of Science and Technology, Wuhan 430072, China.; School of Foreign Languages and Cultures, Chongqing University, Chongqing 400044, China.

The outbreak of COVID-19 (coronavirus disease 2019) has become the focus of attention in the field of urban geography. Built environment, such as the layout of public spaces like transportation hubs and urban open spaces, is an important factor affecting the spread of the epidemic. However, due to the different behavior patterns of different age groups, the intensity and frequency of their use of various built environment spaces may vary. Based on this, we selected patients that were infected, with a non-manipulated time period, and the classification of human behavior patterns; we then conducted a regression analysis study on the spatial distribution and building environment of these COVID-19 patients. The results showed that the spatial distribution of young and middle-aged patients (18-59 years old) was more homogeneous, while the spatial distribution of elderly patients (60 years old and above) had a strong clustering characteristic. Moreover, the significant built environment

2021-05-19

School of Healthcare Technology, Chengdu Neusoft University, Sichuan, China.; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.; School of Life Science and Technology, University of Electronic Science and Technology of China, Sichuan, China.; Center for Informational Biology, University of Electronic Science and Technology of China, Sichuan, China.

The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis. Fundamental studies at genome, transcriptome, proteome, and interactome levels have revealed many viral and host targets for therapeutic interventions. Hundreds of antibodies for treating COVID-19 have been developed at preclinical and clinical stages in the format of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies. Four products, i.e., convalescent plasma, bamlanivimab, REGN-Cov2, and the cocktail of bamlanivimab and etesevimab have been authorized by the U.S. Food and Drug Administration (FDA) for emergency use. Hundreds of relevant clinical trials are ongoing worldwide. Therapeutic antibody therapies have been a very active and crucial part of COVID-19 treatment. In this review, we focus on the progress of therapeutic COVID-19 antibody development and application, discuss corresponding problems

2021-05-13

Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China.; Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, China.; Trinity School of Durham and Chapel Hill, Durham, NC, United States.; Electronic and Computer Engineering, China North Vehicle Research Institute, Beijing, China.; Center for Life Sciences, Tsinghua University, Beijing, China.; Center for Life Sciences, Tsinghua University, Beijing, China.

Although immune dysfunction is a key feature of coronavirus disease 2019 (COVID-19), the metabolism-related mechanisms remain elusive. Here, by reanalyzing single-cell RNA sequencing data, we delineated metabolic remodeling in peripheral blood mononuclear cells (PBMCs) to elucidate the metabolic mechanisms that may lead to the progression of severe COVID-19. After scoring the metabolism-related biological processes and signaling pathways, we found that mono-CD14(+) cells expressed higher levels of glycolysis-related genes (PKM, LDHA and PKM) and PPP-related genes (PGD and TKT) in severe patients than in mild patients. These genes may contribute to the hyperinflammation in mono-CD14(+) cells of patients with severe COVID-19. The mono-CD16(+) cell population in COVID-19 patients showed reduced transcription levels of genes related to lysine degradation (NSD1, KMT2E, and SETD2) and elevated transcription levels of genes involved in OXPHOS (ATP6V1B2, ATP5A1, ATP5E, and ATP5B), which may

2021-04-01

Department of Anesthesiology, China-Japan Friendship Hospital, Beijing, China.; University of Louisville, Louisville, KY.; Peking University Third Hospital, Beijing, China.; Department of Anesthesiology, China-Japan Friendship Hospital, Beijing, China. Electronic address: zhaojing1009@aliyun.com.; University of Colorado, Aurora, CO.

Anesthesiologists have a high risk of infection with COVID-19 during perioperative care and as first responders to airway emergencies. The potential of becoming infected can be reduced by a systematic and integrated approach that assesses infection risk. The latter leads to an acceptable choice of materials and techniques for personal protection and prevention of cross-contamination to other patients and staff. The authors have presented a protocolized approach that uses diagnostic criteria to clearly define benchmarks from the medical history along with clinical symptoms and laboratory tests. Patients can then be rapidly assigned into 1 of 3 risk categories that direct the choice of protective materials and/or techniques. Each hospital can adapt this approach to develop a system that fits its individual resources. Educating medical staff about the proper use of high-risk areas for containment serves to protect staff and patients.CI - Copyright © 2020 The Authors. Published by